Lumimicro Co., Ltd announced that it expects to receive KRW 30 billion in funding from Korea Fixed-Income Investment Advisory, Korea Bond Investment Advisory Co., Ltd.
May 05, 2020
Share
Lumimicro Co., Ltd (KOSDAQ:A082800) announced a private placement of series 16 non-guaranteed private equity convertible bond, series 17 bearer unregistered private convertible bonds for gross proceeds of KRW 10,000,000,000, and 18 bearer unregistered private convertible bonds for gross proceeds of KRW 10,000,000,000, for aggregate gross proceeds of KRW 30,000,000,000 on May 6, 2020. The transaction will include participation from returning investor Korea Fixed-Income Investment Advisory for series 17 and 18 bonds and Korea Bond Investment Advisory Co., Ltd. for series 16 bonds. The series 18 bonds have a coupon rate of 2.1% per annum and series 16 bonds is 1.9% and interest rate of 3.9%. The series 16 and 18 bonds will mature on June 29, 2023. The series 16 and 18 bonds are 100% convertible into 5,344,735 common shares, representing on 4.31% stake in the company at a price of KRW 1,871. The bonds will convert from June 29, 2021 to June 29, 2023. The transaction has been approved by the board of directors. The transaction is expected to close on June 29, 2020.
Vivozon Pharmaceutical Co Ltd , formerly Vivozon Healthcare Inc, is a Korea-based company mainly engaged in the manufacture and sale of finished pharmaceutical products. The Company operates its business through three segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of finished medicines such as external skin preparations, antipyretic analgesic, anti-inflammatory drugs and antidiabetic drugs. The Optical Business segment is engaged in the manufacture and sale of finished products and lighting module sets such as general lighting and automotive lighting using light emitting diode (LED) light sources. The Cosmetics Business segment is engaged in the manufacture and sale of cosmetics and cosmetic ingredients.
Lumimicro Co., Ltd announced that it expects to receive KRW 30 billion in funding from Korea Fixed-Income Investment Advisory, Korea Bond Investment Advisory Co., Ltd.